Senolytics for Secondary Progressive MS
NCT07270120
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis (MS) Secondary Progressive
Interventions
DRUG:
Dasatinib and quercetin
Sponsor
Ohio State University